PD 0332991 inhibited the growth of luminal ER-positive and HER2+ cancer cells, showed synergistic activity with antiestrogen therapy and trastuzumab, and reversed resistance to tamoxifen [40]. This evidence concerns the gene ERBB2 and cancer.